Table 4.
Univariate and multivariate analyses for recurrence-free survival.
| Variable | Univariate | Multivariate | ||
|---|---|---|---|---|
| Hazard Ratio (95% CI) |
P-Value | Hazard Ratio (95% CI) |
P-Value | |
| Age (<56 vs. ≥56) | 3.585 (1.894–6.788) | <0.001 | 3.332 (1.744–6.369) | <0.001 |
| Sex (female vs. male) | 0.280 (0.087–0.902) | 0.033 | ||
| Smoking history (yes vs. no) | 0.812 (0.435–1.516) | 0.514 | ||
| Alcohol history (yes vs. no) | 0.689 (0.389–1.221) | 0.202 | ||
| Performance status (0 vs. 1–2) | 1.061 (0.600–1.876) | 0.838 | ||
| Weight loss (<10% vs. ≥10%) | 0.993 (0.391–2.519) | 0.988 | ||
| Histologic grade (Gx/1/2 vs. G3) | 1.241 (0.615–2.501) | 0.547 | ||
| Tumor location (upper/middle vs. distal) | 1.226 (0.611–2.460) | 0.567 | ||
| Primary tumor length (≤5 vs. >5 cm) | 0.606 (0.336–1.090) | 0.095 | ||
| Clinical TNM stage (II vs. III) | 0.588 (0.263–1.314) | 0.196 | ||
| Chemotherapy regimen a (1 vs. 2/3) | 0.464 (0.258–0.837) | 0.011 | 0.420 (0.228–0.775) | 0.005 |
| Radiation dose (≤40 vs. >40 Gy) | 1.121 (0.524–2.396) | 0.769 | ||
| Radiotherapy modality (3DCRT vs. IMRT) | 1.255 (0.586–2.687) | 0.559 | ||
| IDO1 (negative vs. positive) | 0.236 (0.131–0.427) | <0.001 | 0.282 (0.153–0.519) | <0.001 |
| PD-L1 (negative vs. positive) | 0.509 (0.285–0.907) | 0.022 | ||
| CD8+ TIL density (low vs. high) | 1.748 (0.978–3.126) | 0.060 | ||
| Pathologic response (pCR vs. non-pCR) | 0.401 (0.211–0.764) | 0.005 | ||
Abbreviations: CI, confidence interval; 3DCRT, three-dimensional conformal radiation therapy; IMRT, intensity-modulated radiation therapy; IDO1, indoleamine 2,3-dioxygenase 1; PD-L1, programmed cell death-ligand 1; TIL, tumor-infiltrating lymphocyte; pCR, pathologic complete response. a Chemotherapy regimen: 1, cisplatin/vinorelbine; 2, cisplatin/fluorouracil; 3, cisplatin/taxane.